Viewing nowHugliya Tablets 100mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 113.37mg
Tablet · Prescription medication
Huons Co., Ltd.

MFDS item code 202102409 · Approved 2021.03.17 · Insurance code 670609020
Improves blood glucose control in type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy for initial treatment and can be combined with other diabetes medications such as Metformin in cases of difficult blood sugar control. Additionally, it can be used as an adjunct if blood sugar control is insufficient with Sulfonylureas, Metformin, Thiazolidinediones, or insulin either alone or in combination. This variety of treatment methods effectively improves blood sugar control for patients.
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions after administration, so symptoms such as rashes, hives, or breathing difficulties should prompt immediate consultation with a doctor while taking the medication. This medication can potentially cause acute pancreatitis, a serious pancreatic condition, so patients must inform healthcare providers immediately of any abdominal pain, vomiting, or persistent abdominal discomfort after taking it. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in those who are allergic to this medication or its ingredients. Patients with impaired kidney function may have difficulty excreting the drug, so dosage adjustments or careful use under the guidance of a physician are necessary. When taking this medication, hypoglycemia risk exists; thus, careful monitoring of blood sugar changes is particularly important when used with insulin or Sulfonylureas. If serious joint pain or blistering skin conditions occur, discontinue the medication immediately and consult a specialist. Use during pregnancy or breastfeeding is not recommended, and safety in pediatric patients has not been adequately confirmed. In elderly patients, kidney function may decline, so regular assessments of kidney function before and during use are important. In the case of overdose, general emergency treatment should be initiated, and blood dialysis may be required for drug removal, hence immediate medical attention should be sought.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress and should be kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the efficacy of the medication.
Bright yellow-orange round film-coated tablets
100 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.37mg
Tablet · Prescription medication
Huons Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.